Earlier this month, MedBen Rx clients and their brokers were emailed about an opportunity to receive preferred pricing for the biosimilar for the anti-inflammatory medication Stelara. Depending on the dosage, this biosimilar can reduce the cost of the medication by over 90%.
If you have elected to cover the Stelara biosimilar, coverage will become effective on May 1, 2025. Conversion to the biosimilar from Stelara will require a new prescription, and MedBen Rx will work with both your members and their prescribers to obtain the new prescription for the preferred product.
If you wish to elect coverage but have NOT returned the election form, or choose not to elect this program, please mark the form accordingly and return it to admin@medben.com as soon as possible. If you need an additional form, contact your Account Management team.
One additional reminder: MedBen Rx also offers a Humira biosimilar program that has resulted in substantial savings for our clients and their members. If you haven’